Mesenchymal stem cell expression of interleukin-35 protects against ulcerative colitis by suppressing mucosal immune responses
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 20 (7) , 911-918
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31400764)
- Tianjin City High School Science & Technology Fund Planning Project (20130113)
This publication has 36 references indexed in Scilit:
- Stem cell therapy in inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 2013
- IL-35-mediated induction of a potent regulatory T cell populationNature Immunology, 2010
- Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrityThe Journal of Pathology, 2009
- Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in miceClinical and Experimental Immunology, 2008
- Contextual Regulation of Inflammation: A Duet by Transforming Growth Factor-β and Interleukin-10Immunity, 2008
- The inhibitory cytokine IL-35 contributes to regulatory T-cell functionNature, 2007
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitisJournal of Experimental Medicine, 2006
- Impairment of cardiomyogenesis in embryonic stem cells lacking scaffold protein JSAP1Biochemical and Biophysical Research Communications, 2005
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987